• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Entrada Therapeutics, Inc. - Common Stock (NQ:TRDA)

    5.970 -0.400 (-6.28%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 268,615
    Open 6.340
    Bid (Size) 5.150 (20,000)
    Ask (Size) 6.100 (700)
    Prev. Close 6.370
    Today's Range 5.950 - 6.500
    52wk Range 4.930 - 16.45
    Shares Outstanding 33,197,018
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -40.6%
    -40.6%
    1 Month
    -14.7%
    -14.7%
    3 Month
    -54.8%
    -54.8%
    6 Month
    -43.6%
    -43.6%
    1 Year
    -26.4%
    -26.4%

    More News

    Read More
    News headline image
    Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
    From Pomerantz LLP
    Via GlobeNewswire
    Entrada Therapeutics (NASDAQ:TRDA) Plunges Nearly 48% as Early-Stage DMD Clinical Data Disappoints on Drug Exposure ↗
    Via Chartmill
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile ↗
    Via MarketBeat
    Which stocks are experiencing notable movement on Thursday? ↗
    Via Chartmill
    Top stock movements in today's session. ↗
    Via Chartmill
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    Which stocks are moving before the opening bell on Thursday? ↗
    Via Chartmill
    News headline image
    Entrada Therapeutics Reports First Quarter 2026 Financial Results
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗
    Via The Motley Fool
    News headline image
    Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗
    Via The Motley Fool
    News headline image
    Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Entrada Therapeutics to Present at Upcoming Investor Conferences
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗
    Via The Motley Fool
    Topics Regulatory Compliance

    Frequently Asked Questions

    Is Entrada Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Entrada Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Entrada Therapeutics, Inc. - Common Stock trade on?
    Entrada Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Entrada Therapeutics, Inc. - Common Stock?
    The ticker symbol for Entrada Therapeutics, Inc. - Common Stock is TRDA on the Nasdaq Stock Market
    What is the current price of Entrada Therapeutics, Inc. - Common Stock?
    The current price of Entrada Therapeutics, Inc. - Common Stock is 5.970
    When was Entrada Therapeutics, Inc. - Common Stock last traded?
    The last trade of Entrada Therapeutics, Inc. - Common Stock was at 06/10/26 04:00 PM ET
    What is the market capitalization of Entrada Therapeutics, Inc. - Common Stock?
    The market capitalization of Entrada Therapeutics, Inc. - Common Stock is 198.19M
    How many shares of Entrada Therapeutics, Inc. - Common Stock are outstanding?
    Entrada Therapeutics, Inc. - Common Stock has 198M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.